Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Alpha-9 Oncology has raised $175.0M in total funding. The most recent round was Series C. The last funding was announced in October 2024.
Alpha-9 Oncology's investors include Andreessen Horowitz, General Catalyst, RA Capital Management, Lightspeed Venture Partners, Janus Henderson Investors.
Alpha-9 Oncology is headquartered in Vancouver, Canada.
Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Alpha-9 Oncology is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alpha-9 Oncology — Funding & Investors." VCBacked, October 23, 2024, https://www.vcbacked.co/company/alpha-9-oncology. Accessed August 14, 2026.
VCBacked. (2024). Alpha-9 Oncology — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/alpha-9-oncology
{{cite web |title=Alpha-9 Oncology — Funding & Investors |url=https://www.vcbacked.co/company/alpha-9-oncology |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated